What changed on September 23
T·TIME’s company-issued announcement introduces a cash-pay program for compounded injectable semaglutide and tirzepatide. It extends an existing telehealth business rather than announcing a newly approved medicine. The release emphasizes a price that stays the same when the treating clinician changes the dose.
That distinction sets the scope of this review. We checked the launch against product pages and policies available on September 27. A new service announcement can establish what a company is advertising; it cannot establish clinical effectiveness, dispensing quality or how reliably support responds after enrollment.
Read three months alongside the monthly figure
The semaglutide page advertises $99 per month and the tirzepatide page $149, each tied to a three-month plan that renews automatically. The pages include clinician review, medication if prescribed, follow-up and shipping, and say there is no membership fee.
At those advertised rates, three months corresponds to $297 or $447. Treat that as plan arithmetic and confirm the actual charge and billing date before paying. A fixed price across doses is also not a promise that treatment will be prescribed or continued; the clinical assessment remains a separate decision.
The product headline needs the policy beside it
The product pages describe a full treatment-program refund for medical rejection. The broader refund policy lists exclusions such as laboratory services, shipping and services already rendered. It also specifies a $70 GLP-1 physician fee when a patient cancels after intake has been sent for review, and says an order becomes final when the prescription reaches the pharmacy.
Ask which of those charges, if any, apply to the chosen GLP-1 plan and request the answer before payment. Medical rejection, voluntary cancellation and cancellation after prescribing are different events. We would retain the product-page offer and the applicable policy together rather than interpret a short refund headline as covering every circumstance.
A platform and a clinical practice have different roles
The terms of use describe T·TIME as a non-clinical platform and place treatment decisions with independent clinical providers. The refund policy also says incomplete intake or missed follow-up does not automatically pause a subscription. Leaving a questionnaire unfinished should therefore not be treated as a cancellation method.
Identify the treating provider, dispensing pharmacy and support channel for your state. If another professional already manages your medicines, explain that during assessment. We have not independently verified the credentials of a particular assigned professional or tested the subscription workflow, so the published process should not be mistaken for a completed service test.
Keep the launch claim separate from drug evidence
Compounded preparations are not FDA-approved finished products. The presence of research references on a product page does not mean that this newly launched service or its formulations were the subject of those trials. Our study-registry review explains how to trace the product and study behind a research claim.
The newsworthy feature is a newly announced pricing and care model with a stated three-month term. Its consumer value will depend on the prescription, actual charges and follow-up received. For now, the strongest conclusion supported by the public record is about the offer’s structure; patient outcomes and service performance remain outside this review.
Common questions
Did T·TIME announce a newly approved GLP-1 drug?
No. Its September release announces a telehealth program for compounded preparations.
Does abandoning intake stop billing?
The refund policy says incomplete intake or follow-up does not automatically pause or cancel a subscription. Use the stated support process and obtain confirmation.
Sources and fact-checking
Sources checked 2026-09-27. Company pages document their own published terms; government and research sources provide context. This is a review of published information, not a hands-on service test or a clinical evaluation. Prices and availability can change.